This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The transaction is expected to close in Q2 FY 2026
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
Sun Pharma gets 8 observations from USFDA for Halol facility
The company received one observation in the Form-483
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
Conceptulised by Lowe Lintas, the new campaign creatively brings the "fast action" benefit of Cipladine to life through a series of films
Subscribe To Our Newsletter & Stay Updated
